John B. Green Sells 12,500 Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Stock

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) CFO John B. Green sold 12,500 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $21.05, for a total transaction of $263,125.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

John B. Green also recently made the following trade(s):

  • On Thursday, November 14th, John B. Green sold 3,562 shares of Dicerna Pharmaceuticals stock. The shares were sold at an average price of $20.00, for a total transaction of $71,240.00.
  • On Thursday, October 31st, John B. Green sold 12,500 shares of Dicerna Pharmaceuticals stock. The shares were sold at an average price of $18.00, for a total transaction of $225,000.00.

Shares of NASDAQ DRNA opened at $23.09 on Friday. The firm has a market capitalization of $1.64 billion, a P/E ratio of -19.24 and a beta of 2.29. Dicerna Pharmaceuticals Inc has a one year low of $9.31 and a one year high of $24.10. The company’s fifty day moving average is $16.86 and its two-hundred day moving average is $14.66.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.15). The company had revenue of $8.04 million for the quarter, compared to analysts’ expectations of $11.70 million. Dicerna Pharmaceuticals had a negative return on equity of 58.92% and a negative net margin of 541.24%. As a group, equities research analysts forecast that Dicerna Pharmaceuticals Inc will post -1.37 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Dicerna Pharmaceuticals by 52.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,363 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,151 shares in the last quarter. Quantamental Technologies LLC boosted its position in shares of Dicerna Pharmaceuticals by 94.4% in the 2nd quarter. Quantamental Technologies LLC now owns 3,500 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 1,700 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of Dicerna Pharmaceuticals by 7.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 28,161 shares of the biopharmaceutical company’s stock worth $444,000 after buying an additional 1,871 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Dicerna Pharmaceuticals by 0.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 302,337 shares of the biopharmaceutical company’s stock worth $4,762,000 after buying an additional 1,881 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its position in shares of Dicerna Pharmaceuticals by 17.0% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 21,334 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 3,100 shares in the last quarter. Institutional investors own 87.24% of the company’s stock.

DRNA has been the topic of several recent research reports. Leerink Swann reissued an “outperform” rating and issued a $30.00 price objective (up from $26.00) on shares of Dicerna Pharmaceuticals in a research note on Tuesday. Chardan Capital restated a “buy” rating and set a $18.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, August 13th. SunTrust Banks boosted their target price on shares of Dicerna Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday. HC Wainwright restated a “buy” rating and set a $30.00 target price (up from $22.00) on shares of Dicerna Pharmaceuticals in a research report on Tuesday. Finally, Robert W. Baird started coverage on shares of Dicerna Pharmaceuticals in a research report on Tuesday, October 29th. They set an “outperform” rating and a $27.00 target price on the stock. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Dicerna Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $24.50.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Article: Dividend Aristocrat Index

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.